What is the purpose of the Filgrastim 300mcg Injection?
Filgrastim 300mcg Injection is used to treat neutropenia (a low number of white blood cells) caused by cancer drugs. It’s a synthetic (man-made) version of a molecule called a colony-stimulating factor, which is naturally created in your body. Filgrastim aids in the production of new white blood cells in the bone marrow.
Filgrastim 300mcg Injection is given where?
Filgrastim 300mcg Injection can be injected subcutaneously (between the skin and the muscle) or infused into a vein (intravenous, IV). Filgrastim is usually used once a day. Your doctor will choose the number of days you will receive filgrastim.
What are filgrastim’s side effects?
- Fever, cough,
- difficulty breathing;
- nosebleeds; bone, muscle, or joint discomfort; diarrhea;
- rash and thinning hair are all common adverse effects.
When should I get a Filgrastim 300mcg Injection shot?
Start taking the drug at least 24 hours after your chemotherapy has finished. However, do not take it within 24 hours of starting another chemotherapy treatment. Allow 30 minutes for the drug to come to room temperature before injecting it.
How long does filgrastim take to take effect?
It takes about 24 hours to reach peak plasma levels after injection, although it can take anywhere from 16 to 120 hours. It takes around 24 hours to induce peak numbers of neutrophils.
Is filgrastim a source of fatigue for you?
A fatigued feeling, a rash on the skin, nosebleeds, or an allergic reaction to the injection site (redness, swelling, itching, lumps, or bruising).
Filgrastim is administered 24 hours after chemotherapy for a reason.
To accelerate the formation of new, healthy white blood cells, this medicine is normally given at least 24 hours following chemotherapy (WBC). Pegfilgrastim is a longer-acting version of filgrastim that should not be given within 14 days following chemotherapy.
Filgrastim is taken after chemotherapy for a reason.
Filgrastim injection products (Granix, Neupogen, Nivestym, Zarxio) are used to reduce the risk of infection in people who have non-myeloid cancer (cancer that does not affect the bone marrow) and are taking chemotherapy that may reduce the number of neutrophils (a type of blood cell that helps fight infection).